Theory Paper IIDrNB Cardiology – Theory Notes

BRUGADA SYNDROME; CURRENT STATUS

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IINTRODUCTION AND EPIDEMIOLOGY (ESC 2022)

  • Definition: Brugada Syndrome (BrS) (first described by Pedro and Josep Brugada in 1992) is an inherited arrhythmogenic syndrome characterized by a coved-type ST-segment elevation (Type 1 pattern) in the right precordial leads (V1–V2) and an increased risk of Sudden Cardiac Death (SCD) due to polymorphic Ventricular Tachycardia (pVT) or Ventricular Fibrillation (VF) in patients without overt structural cardiomyopathy.
  • Epidemiology: Inherited in an autosomal dominant pattern with incomplete, age- and sex-dependent penetrance (and strong polygenic modulation). Despite equal genetic transmission between sexes, clinical phenotype expression is 8- to 10-fold higher in adult males than females (driven by higher androgen-mediated Ito density in males) and peaks in the 3rd to 4th decade of life (mean age of VF arrest ~41 years), predominantly occurring at night during sleep or rest (periods of heightened vagal/parasympathetic tone and bradycardia) or during febrile illnesses (historic nocturnal sudden unexplained death syndrome: Bangungut in the Philippines, Pokkuri in Japan, and Lai Tai in Thailand).

IIPATHOPHYSIOLOGY AND GENETIC SUBSTRATE

  • Genetic Architecture: Pathogenic loss-of-function variants in SCN5A (chromosome 3p22, encoding the alpha-subunit of the cardiac voltage-gated sodium channel Nav1.5) account for 20 to 30 percent of diagnosed BrS probands. In 2018, the ClinGen expert curation panel concluded that SCN5A is the only gene with definitive monogenic evidence for BrS (the other 20 curated genes had only limited or disputed evidence), while Genome-Wide Association Studies (GWAS) prove that common variants at SCN5A, SCN10A, HEY2, and MAPRE2 form a Polygenic Risk Score that dictates ECG penetrance.
  • Two Complementary Cellular Hypotheses:
    • The Repolarization Hypothesis (Antzelevitch): Reduction in inward sodium current (INa) leaves the prominent transient outward potassium current (Ito) in the RVOT epicardium unopposed during Phase 1 of the action potential. This causes loss of the Phase 2 action potential dome selectively in RVOT epicardial cells (while endocardial cells retain the dome), creating a transmural voltage gradient (manifesting as coved J-point/ST elevation) and Phase 2 re-entry that triggers closely coupled PVCs and polymorphic VT/VF.
    • The Depolarization / Micro-Structural Hypothesis (Wilde & Coronel / Nademanee): Conduction delay, interstitial micro-fibrosis, and reduced Connexin-43 (Cx43) gap-junction expression localized specifically to the anterior epicardium of the RVOT cause delayed, fractionated activation (manifesting as late potentials and coved ST elevation) that supports anatomical re-entry—providing the direct target for epicardial catheter ablation.

IIIDIAGNOSTIC ALGORITHM, HIGH-LEAD PLACEMENT AND PROVOCATION TESTING

  • Diagnostic Type 1 (“Coved”) vs. Non-Diagnostic Type 2 (“Saddleback”) ECG:
    • Type 1 Brugada ECG (Only Diagnostic Morphology): Coved J-point/ST-segment elevation >= 2 mm (0.2 mV) followed by a concave/straight descent into a negative T wave in >= 1 right precordial lead (V1 and/or V2) placed in the standard 4th, 3rd, or 2nd intercostal space.
    • High Right Precordial Lead Placement (2nd and 3rd ICS): Moving leads V1 and V2 superiorly to the 2nd and 3rd intercostal spaces places the electrodes directly over the high anatomical position of the RVOT, doubling diagnostic sensitivity.
    • Exclusion of Brugada Phenocopies: Acute anterior/RV myocardial ischemia, pulmonary embolism, hyperkalemia, hypercalcemia, arrhythmogenic right ventricular cardiomyopathy (ARVC), pectus excavatum, and mechanical compression of the RVOT must be excluded.
    • Pharmacological Sodium Channel Blocker Challenge (Unexplained Cardiac Arrest and Family Screening; Shanghai Score >=3.5 Required if Drug-Induced):
    • Agents and Dosing: Ajmaline (1 mg/kg IV over 5 to 10 minutes — highest sensitivity ~80–90% and ultra-short half-life), Flecainide (2 mg/kg IV over 10 minutes, max 150 mg, or 400 mg oral), or Procainamide (10 mg/kg IV over 10 minutes) under continuous 12-lead (including high V1–V2) ECG monitoring with a defibrillator and IV Isoproterenol + 8.4% Sodium Bicarbonate at the bedside.
    • Mandatory Immediate Termination Criteria: (1) Development of a diagnostic Type 1 Brugada ECG; (2) Development of frequent PVCs or ventricular arrhythmias; (3) QRS widening to >= 130 percent of baseline (or additional Type 2 ST elevation >=2 mm); or (4) Completion of the full drug infusion.
Clinical / ECG Scenario ESC 2022 Guideline Class Recommended Management Strategy
All BrS Patients (General Measures) Class I Avoid brugadadrugs.org agents, cocaine, & heavy alcohol; treat any fever immediately with antipyretics
Aborted Cardiac Arrest or Sustained VT/VF Class I (Level C) ICD Implantation (Transvenous or Subcutaneous S-ICD)
Spontaneous Type 1 ECG + Arrhythmic Syncope Class IIa (Level C) ICD Implantation (Use ILR [Class IIa] if syncope is unexplained/equivocal)
Asymptomatic + Spontaneous Type 1 ECG Class IIb (Level B) Programmed Electrical Stimulation (PES) (up to 2 extrastimuli) may be considered; ICD if VF inducible
Electrical Storm (Acute >=3 VF in 24 h) Class IIa (Level C) IV Isoproterenol infusion (1–2 mcg/min) + initiate oral Quinidine + cool fever/correct K+
Recurrent ICD Shocks / Storm (Chronic) Class IIa (Level B/C) Oral Quinidine (300–600 mg q6–8h) AND/OR Epicardial RVOT Substrate Catheter Ablation
Asymptomatic + Drug-Induced Type 1 Only Class III (No ICD) Very low event rate (<0.1–0.3%/yr); lifestyle/fever precautions only (PES and ICD not recommended)

IVRISK STRATIFICATION, ELECTRICAL STORM AND EPICARDIAL ABLATION

  • Hierarchy of Annual Arrhythmic Event Rates:
    • Aborted SCA Survivors: ~7.7 percent per year (FINGER registry) (Class I ICD).
    • Spontaneous Type 1 ECG + Arrhythmic Syncope: ~2 to 3 percent per year (Class IIa ICD).
    • Asymptomatic Spontaneous Type 1 ECG: ~0.5 to 1.0 percent per year (additional ECG risk markers include fragmented QRS [fQRS], prominent S wave in Lead I [amplitude >=0.1 mV or duration >=40 ms, reflecting RVOT conduction delay], aVR sign [R wave >=0.3 mV in aVR], concomitant inferolateral early repolarization, and sinus node dysfunction).
    • Asymptomatic Drug-Induced Type 1 ECG Only: <0.1 to 0.3 percent per year (reassurance and fever/drug avoidance only).
    • Emergency Management of Brugada Electrical Storm (>=3 VT/VF Episodes in 24 Hours):
    • Step 1 — ICU Admission and Trigger Eradication: Immediately lower body temperature (IV Paracetamol + active cooling blankets), normalize serum Potassium (>4.0 to 4.5 mEq/L) and Magnesium, sedate to suppress anxiety/vagal swings, and reprogram the ICD to avoid shocks on non-sustained episodes.
    • Step 2 — Intravenous Isoproterenol Infusion (First-Line Acute Drug — Class IIa): Start Isoproterenol at 1 to 2 mcg/min IV (targeting a 20 percent increase in baseline sinus rate to 90–110 bpm), which boosts inward L-type calcium current (ICa-L), restores the epicardial action potential dome, and rapidly suppresses VF storm (in contrast to catecholaminergic arrhythmias like LQTS/CPVT where isoproterenol is harmful).
    • Step 3 — Oral Quinidine Loading (Class IIa): Administer Hydroquinidine / Quinidine Sulfate (blocks Ito) while weaning Isoproterenol over 48 to 72 hours.
    • Step 4 — Epicardial RVOT Substrate Catheter Ablation (ESC 2022 Class IIa): Performed via percutaneous subxiphoid pericardial access; eliminates fractionated late potentials over the anterior RVOT epicardium, normalizing the Type 1 ECG and keeping 96 percent of patients VF-free after one or more procedures (BRAVO Registry, Circulation 2023) (Class III caveat: Catheter ablation is not recommended in asymptomatic BrS patients).

Key references

  • Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al.: 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, European Heart Journal, 2022.
  • Nademanee K, Veerakul G, Chandanamattha P, et al.: Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium, Circulation, 2011 / BRAVO Registry, Circulation, 2023.
  • Hosseini SM, Kim R, Udupa S, et al. (ClinGen Consortium): Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene-Disease Validity for Brugada Syndrome, Circulation, 2018.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.